How should women with a BRCA1 mutation without breast cancer be managed? 🧠💬

Halle Moore (@HalleMooreMD, @ClevelandClinic) breaks down surveillance vs preventive surgery—and why fertility plans & patient preferences must guide decisions.

Watch: … https://twitter.com/i/web/status/2017145872098754623

Managing cancer risk in BRCA1 mutation carriers without prior breast cancer

Halle Moore, MD, Cleveland Clinic, Cleveland, OH, comments on management options for women with a known BRCA1 mutati...

ow.ly

Ryan Sullivan at #ESMO25 explores individualized neoantigen therapies & vaccines in #Melanoma 🎯 These approaches may boost efficacy without raising autoimmune toxicity, unlike combined checkpoint blockade regimens ⚡💉

Watch the insights 🎥

#melsm… https://twitter.com/i/web/status/2016934651206484000

What are the benefits of integrating cancer vaccines into clinical practice?

Ryan Sullivan, MD, Massachusetts General Hospital, Boston, MA, discusses the potential benefits of individualized neoantig...

ow.ly

Comparing #ADCs in #BreastCancer isn’t easy, as data are limited. François Poumeaud explains why switching targets or payloads may unlock added benefit, and why reliance on TOP1 inhibitors is a current bottleneck. More flexibility ahead?

Watch: … https://twitter.com/i/web/status/2016783499169014217

Challenges and future directions of ADC targets and payloads in breast cancer

Francois Poumeaud, MD, Oncopole Claudius Regaud, Toulouse, France, comments on the challenges of comparing different ant...

ow.ly

How do we define the right strategy for neuroendocrine carcinomas? 🤔🔬

Juan Manuel O’Connor (@Juanmaoconnor) highlights the need for clear control arms to guide adjuvant vs neoadjuvant decisions, and tailoring surgery to tumor origin & patient context.

Watch for insights 👇…

Optimizing treatment strategies for neuroendocrine carcinomas

Juan Manuel O'Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, comments on the challenges of det...

twitter.com